Patent · US Expired

Substituted 4,5-dihydro-6-[4-(1H-imidazol-1-yl)phenyl]-3(2H)-pyridazinones and 6-[4-(1H-imidazol-1-yl)phenyl]-3(2H)-pyridazinones

US4353905A · kind A · utility

35Cited by

4References

6Claims

0Family size

Assignee

WARNER-LAMBERT COMPANY LLC · US

Inventors

Ila Sircar · Ann Arbor, US
James A. Bristol · Ann Arbor, US

Key dates

Filing date	Sep 17, 1981
Grant date	Oct 12, 1982
Priority date	—
Expiry date	Sep 17, 2001

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07D249/08
WIPO fieldOrganic fine chemistry
WIPO sectorChemistry

Abstract

Substituted 4,5-dihydro-6-[4-(1H-imidazol-1-yl)-phenyl]-3(2H)-pyridazinone compounds and 6-[4-(1H-imidazol-1-yl)phenyl]-3(2H)-pyridazinone compounds and pharmaceutically acceptable salts thereof are useful as cardiotonic agents. Said compounds cause a significant increase in myocardial contractility in the anesthetized dog. Said compounds are produced by reacting substituted .gamma.-oxo-benzenebutanoic acids with suitably substituted hydrazines to provide 4,5-dihydro-6-[4-(1H-imidazol-1-yl)phenyl]-3(2H)-pyridazinones which are dehydrogenated to 6-[4-(1H-imidazol-1-yl)phenyl]-3(2H)-pyridazinones. Both the intermediate 4,5-dihydro-6-[4-(1H-imidazol-1-yl)phenyl]-3(2H)-pyridazinones and the 6-[4-(1H-imidazol-1-yl)phenyl]-3(2H)-pyridazinones are useful as cardiotonic agents.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.